AVN 67.98 Decreased By ▼ -2.75 (-3.89%)
BOP 9.88 Increased By ▲ 0.33 (3.46%)
CHCC 133.50 Increased By ▲ 4.25 (3.29%)
DCL 11.55 Increased By ▲ 0.15 (1.32%)
DGKC 114.35 Increased By ▲ 3.40 (3.06%)
EFERT 60.10 Increased By ▲ 0.30 (0.5%)
EPCL 44.00 Decreased By ▼ -0.70 (-1.57%)
FCCL 20.90 Increased By ▲ 0.07 (0.34%)
FFL 17.65 Decreased By ▼ -0.54 (-2.97%)
HASCOL 21.17 Increased By ▲ 0.04 (0.19%)
HBL 133.00 Increased By ▲ 0.95 (0.72%)
HUBC 81.55 Decreased By ▼ -0.59 (-0.72%)
HUMNL 8.21 Increased By ▲ 0.20 (2.5%)
JSCL 29.91 Increased By ▲ 2.51 (9.16%)
KAPCO 26.90 Increased By ▲ 0.54 (2.05%)
KEL 4.13 No Change ▼ 0.00 (0%)
LOTCHEM 12.90 Decreased By ▼ -0.03 (-0.23%)
MLCF 40.17 Increased By ▲ 1.18 (3.03%)
OGDC 108.25 Decreased By ▼ -1.02 (-0.93%)
PAEL 38.10 Increased By ▲ 0.13 (0.34%)
PIBTL 13.62 Increased By ▲ 0.20 (1.49%)
PIOC 99.00 Increased By ▲ 3.25 (3.39%)
POWER 9.24 Increased By ▲ 0.10 (1.09%)
PPL 95.27 Decreased By ▼ -0.89 (-0.93%)
PSO 202.00 Increased By ▲ 0.49 (0.24%)
SNGP 65.40 Increased By ▲ 1.06 (1.65%)
STPL 14.31 Increased By ▲ 1.06 (8%)
TRG 56.55 Decreased By ▼ -0.33 (-0.58%)
UNITY 17.61 Decreased By ▼ -0.45 (-2.49%)
WTL 1.22 No Change ▼ 0.00 (0%)
BR100 4,355 Decreased By ▼ -5.18 (-0.12%)
BR30 22,224 Increased By ▲ 12.41 (0.06%)
KSE100 41,876 Increased By ▲ 47.35 (0.11%)
KSE30 17,674 Decreased By ▼ -22.51 (-0.13%)
COVID-19 TOTAL DAILY
CASES 288,047 747
DEATHS 6,162 9

Russia aims to produce 'millions' of virus doses by 2021

  • Gamaleya's vaccine is a so-called viral vector vaccine, meaning it employs another virus to carry the DNA encoding of the needed immune response into cells.
03 Aug 2020

MOSCOW: Russia said Monday it aims to launch mass production of a coronavirus vaccine next month and turn out "several million" doses per month by next year.

The country is pushing ahead with several vaccine prototypes and one prepared at the Gamaleya institute in Moscow has reached advanced stages of development.

"We are very much counting on starting mass production in September," industry minister Denis Manturov said in an interview published by TASS news agency.

"We will be able to ensure production volumes of several hundred thousand a month, with an eventual increase to several million by the start of next year," he said, adding that one developer is preparing production technology at three locations in central Russia.

Health Minister Mikhail Murashko on Saturday said the Gamaleya vaccine had "completed clinical trials" and that documents were being prepared to register it with the state.

Another vaccine, developed by Siberia-based Vektor lab, is currently undergoing clinical trials and two more will begin human testing within the next two months, Murashko said.

Gamaleya's vaccine is a so-called viral vector vaccine, meaning it employs another virus to carry the DNA encoding of the needed immune response into cells.

Gamaleya's vaccine employs the adenovirus, a similar technology to the coronavirus vaccine prototype developed by China's CanSino, currently in the advanced stage of clinical trials.

The Gamaleya institute came under fire after researchers and directors injected themselves with the prototype months ago, with specialists criticising the move as an unorthodox and rushed way of starting human trials.

Scientists have told AFP that Russia will struggle to adapt the vaccine to mass production because the country lacks raw materials, adequate facilities and experience, particularly with advanced technology like viral vector.

Some Russian officials have boasted that the country will be the first to come up with the vaccine, even comparing it to the space race to produce the first satellite in the Soviet era.

Moscow has dismissed allegations from the UK, the United States and Canada that a hacking group linked to Russian intelligence services tried to steal information about a coronavirus vaccine from labs in the West.

Russia's coronavirus caseload is currently fourth in the world after the United States, Brazil and India.